On January 9, 2024, Lotus Health (600186) released its 2023 annual performance forecast, which is expected to reach 12,000 in 2023000000 to 150000000000000000000000000000000000092% to 22491%。It is expected that the net profit after deducting non-recurring gains and losses in 2023 will be 11,500000000 to 135000000000000000000000000000000000040% to 11647%。
The financial data of this performance forecast has not been audited by the auditor. According to Lotus Health Industry Group Co., Ltd., the current performance forecast is suitable for the situation of achieving profitability and net profit increasing by more than 50% compared with the same period last year.
In the same period last year, the company achieved a net profit attributable to shareholders of listed companies of 4616720,000 yuan, net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 6236300,000 yuan.
The company said that the main reason for the expected increase in performance is that during the reporting period, the company implemented the "brand revival strategy", which made product sales maintain a high growth rate, the main business achieved quality improvement and quantity growth, and the market share was further improved. The company has promoted the continuous improvement of business development by insisting on solid innovation and continuous deepening reform. Lotus Health Industry Group Co., Ltd. said that there are no false records, misleading statements or major omissions in the content of this performance forecast, and assumes legal responsibility for the authenticity, accuracy and completeness of its content. The 2023 annual performance forecast released by Lotus Health Industry Group Co., Ltd. provides investors with a reference for investment decisions.
The above content and data have nothing to do with the position of the interface and do not constitute investment advice. Do so at your own risk.